White Papers
In the pharmaceutical industry, there has been ongoing discussion whether the Commercial Operations departments should become a globalized function. Over the past decade as companies have become more global in commercializing their products, organizations have been investigating the effectiveness of the Commercial Operations ecosystem.
For 20 years, TGaS Advisors, a Division of Trinity Life Sciences, has been working with U.S. Commercial Operations leaders in the pharmaceutical industry, providing benchmarks and insights across 9 capability areas/departments and over 50 unique functions.…
Read Now
White Papers
Navigating the MarTech Jungle: An Analysis of The Technology Powering 160+ Pharma Brands.
In today’s hyperconnected digital landscape, the marketing technology (MarTech) space has exploded into a complex ecosystem of over 10,000 potential vendors and services. The sheer volume of available options presents opportunities for pharmaceutical brands to optimize their performance and gain a competitive advantage.
In this white paper, TGaS has meticulously reviewed the technology powering 160+ patient websites to understand which tools are leading in their respective categories…
Read Now
White Papers
This report, the fifth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2019, scoring each on its commercial performance, therapeutic value, and R&D investment. 2019 saw 53 unique drug and biologic approvals, of which the majority were neurology (~23%) followed by oncology (~21%). In this…
Read Now
White Papers
Pharmaceutical companies that are seeking ways to engage and partner with integrated delivery networks must understand this: IDNs are evolving in ways that have a profound effect on how healthcare is managed, what care paths are followed and which populations are carved out for special attention.
TGaS Advisors, a division of Trinity Life Sciences, conducted 15 in-depth interviews with key decision-makers from advanced healthcare systems in the U.S. to understand their perspectives on what is driving IDNs and what they…
Read Now
White Papers
Gene therapies’ single administration nature presents a unique commercial challenge for biopharmaceutical companies; unlike traditional small molecule or biologic therapies that can be dosed chronically or repeatedly on an “as needed” basis, the one-time per patient administration of a gene therapy means that as time passes, the eligible population decreases in size.
In this white paper, Trinity Life Sciences’ cell and gene therapy experts explore the unique opportunities that life sciences executives can utilize to unlock eligible patient populations and…
Read Now
White Papers
Trinity Life Sciences’ Evidence, Value, Access and Pricing experts identify the key global market access trends that will enable life sciences executives to identify opportunities, combat challenges and ultimately secure success in 2023.
Download this white paper to understand:
The five key market access trends emanating from 2022 that foretell the opportunities and challenges that lie ahead in 2023 (and beyond).
In-depth insights from 11 U.S. and 24 ex-U.S. payers from Trinity Life Sciences’ ‘Global Market Access Payer Survey’.
How…
Read Now
White Papers
As the market becomes increasingly crowded and budget constraints continue in China, downward pricing pressure to secure National Reimbursement Drug List (NRDL) inclusion remains the top challenge for multinational pharma companies in this market. However, the significant uptake post-NRDL inclusion and broad access offer substantial opportunities for innovative products with clinical differentiation.
In this white paper, Trinity Life Sciences explores the highlights of the 2021 NRDL negotiation; including trends within the oncology, rare disease and chronic disease therapeutic areas…
Read Now
White Papers
Digital therapeutics (DTx) are impacting how patients are treated, interact with their providers and think about their own health. DTx have garnered interest from the investment community as well as pharma companies seeking an integrated digital offering. However, payers have not yet established a clear framework for integrating these technologies in their plans.
Coverage of DTx to date has been limited and the outlook for it is unclear. We spoke to four medical and pharmacy directors from large payer organizations…
Read Now
White Papers
With more momentum than ever to bring innovative medicines to market, there is increased pressure on emerging companies to get the launch right. The industry has seen record-breaking funding for therapies in recent years, and many have been commercialized by emerging biopharma companies launching for the first time. For many of these emerging biopharma companies, optimizing commercial launch spend is a critical consideration pre- and post-launch, and with limited funds it can be easy to misjudge the timing of key…
Read Now
White Papers
In 2018, Trinity Life Sciences published a white paper titled, How to Approach Asset Valuation in Pharma & Biotech: Putting a price tag on emerging therapies. At the time, pharma and biotech firms were seeing venture investment growth of ~20% per year. This trend has only accelerated alongside the value of co-developments, partnerships, joint ventures, licensing agreements and other deals nearly doubling from 2019 to 2020. Quantifying the value of underlying assets throughout the clinical development process remains vital to…
Read Now
